Compare AMTB & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | PHAT |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 776.2M | 942.6M |
| IPO Year | N/A | 2019 |
| Metric | AMTB | PHAT |
|---|---|---|
| Price | $20.07 | $17.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $21.75 | $17.33 |
| AVG Volume (30 Days) | 226.1K | ★ 874.8K |
| Earning Date | 01-21-2026 | 10-30-2025 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $388,504,000.00 | $147,190,000.00 |
| Revenue This Year | $61.42 | $220.37 |
| Revenue Next Year | $2.10 | $83.14 |
| P/E Ratio | $12.72 | ★ N/A |
| Revenue Growth | 51.98 | ★ 460.30 |
| 52 Week Low | $15.62 | $2.21 |
| 52 Week High | $24.40 | $18.31 |
| Indicator | AMTB | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 66.74 |
| Support Level | $20.09 | $16.77 |
| Resistance Level | $20.50 | $18.31 |
| Average True Range (ATR) | 0.48 | 0.88 |
| MACD | -0.07 | 0.26 |
| Stochastic Oscillator | 45.61 | 79.95 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.